Jefferies raises target for Gilead Sciences stock from USD 184.00 to USD 185.00

Published on 10/27/2026 at 18:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are scheduled for October 29, 2026. Gilead Sciences stock costs EUR 141.71 on October 27, 2026, plus 0.06 percent versus the Xetra close.

Analyst target and earnings date

Jefferies raised its Gilead Sciences target from USD 184.00 to USD 185.00 on October 23, 2026.
Gilead Sciences lists third-quarter 2026 results for October 29, 2026.
Gilead Sciences stock costs EUR 141.71 at Lang & Schwarz on October 27, 2026 at 6:06 p.m. CEST, plus 0.06 percent versus the Xetra close of EUR 141.62.
Second-quarter revenue was USD 7.80 billion versus USD 7.40 billion expected.

Gilead Sciences, US3755581036, Illustration mit AI erstellt.

Jefferies raised its Gilead Sciences price target from USD 184.00 to USD 185.00 on October 23, 2026, while maintaining a Buy rating, according to Investing.com. Against the Nasdaq price of USD 157.87 on October 27, 2026, the new target is 17.18 percent above the price. Gilead Sciences stock was trading at EUR 141.71 at Lang & Schwarz on October 27, 2026 at 6:06 p.m. CEST, plus 0.06 percent versus the Xetra close of October 27, 2026 at EUR 141.62.

Results arrive on October 29

Gilead Sciences lists its third-quarter 2026 earnings presentation for October 29, 2026 at 4:30 p.m. ET, according to the company's website, which makes the reporting date the next scheduled event for the stock. The date follows a second quarter in which revenue reached USD 7.80 billion, compared with USD 7.40 billion expected, according to MarketBeat on October 20, 2026.

Stock stays below the yearly high

On the Nasdaq, Gilead last traded at USD 157.87 on October 27, 2026 at 1:09 p.m. ET. The primary-market 52-week range was USD 114.02 to USD 160.51, placing the price 1.64 percent below the high and 38.46 percent above the low. The Xetra quote showed a day range of EUR 140.46 to EUR 142.00 and volume of 490 shares on October 27, 2026.

Valuation meets a near-term catalyst

Gilead's market capitalization was USD 195.8 billion and its price-to-earnings ratio was minus 59.13 on October 27, 2026. The negative ratio reflects the loss reported for the second quarter, when net income attributable to common shareholders was minus USD 10.50 billion and diluted earnings per share were minus USD 8.45, according to the standardized quarterly figures for the period ended June 30, 2026.

Comparison with peers

Gilead Sciences: plus 0.06 percent versus the Xetra close, P/E minus 59.13, market capitalization USD 195.8 billion, October 27, 2026.
AbbVie (NYSE, USD): minus 0.16 percent, P/E 80.66, market capitalization USD 505.9 billion, October 27, 2026.
Amgen (NASDAQ, USD): plus 0.66 percent, P/E 27.82, market capitalization USD 242.0 billion, October 27, 2026.

Target distance and earnings date

The analyst target provides the clearest valuation reference ahead of the October 29 results. Jefferies also cited Gilead's acquisition of PepStar Therapeutics' HCXT-2001 program for USD 1.28 billion in cash, while the program remains in early Phase 1 development, according to Investing.com on October 23, 2026.